Fostamatinib selected for National Institutes of Health ACTIV-4 (Accelerating COVID-19 Therapeutic Interventions and Vaccines) trial in US
Fostamatinib, a novel oral spleen tyrosine kinase inhibitor, has been selected for this trial evaluating treatments that aim to protect and heal host tissues in hospitalised patients with COVID-19. An emergency use authorization has already been submitted to FDA.
Source:
Biospace Inc.